

SUPPLEMENTARY MATERIAL


Supplementary Table 1 – Immunohistochemical study: Antibodies and protocols

found in our PLCIS series

Antibody	Origin	Clone	Dilution	Incubation	Retrieval	Detection	Staining Location	Scoring
ER*	Dako	1D5	1:100	30min	EDTA pH9.0	Horse radish peroxidase polymer	Nuclear	Any positivity
HER2**	Dako	Rabbit	as per kit	30min	EDTA pH9.0	Horse radish peroxidase polymer	Membranous	Herceptest
E-cadherin***	Dako	NCH- 38	1:50	30min	Citrate pH6.0	Horse radish peroxidase polymer	Membranous	Any positivity

*ER was considered positive if any nuclear staining was present [1]. **HER2/neu was scored on a 0 to 3+ scale using ASCO/CAP test guideline recommendations [2]. FISH for HER2 was not performed for the equivocal case. ***E-cadherin was interpreted as either negative or positive based on the absence or presence of membranous immunoreactivity in the cells of interest, with evaluation of appropriate internal controls. Myoepithelial cells intermixed with LCIS cells were excluded from this analysis [1].

Supplementary Figure 1 – Patient flow diagram representative of the database search for consecutive cases of variants of LCIS from 1995 to 2012



Supplemental References

1. Morrogh M, Andrade VP, Giri D, Sakr RA, Paik W, Qin LX, Arroyo CD, Brogi E, Morrow M, King TA (2012) Cadherin-catenin complex dissociation in lobular neoplasia of the breast. *Breast Cancer Res Treat* 132:641-652. doi:10.1007/s10549-011-1860-0
2. Wolff AC, Hammond ME, Hicks DG, Dowsett M, McShane LM, Allison KH, Allred DC, Bartlett JM, Bilous M, Fitzgibbons P, Hanna W, Jenkins RB, Mangu PB, Paik S, Perez EA, Press MF, Spears PA, Vance GH, Viale G, Hayes DF, American Society of Clinical O, College of American P (2013) Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. *J Clin Oncol* 31:3997-4013. doi:10.1200/JCO.2013.50.9984